You are leaving the Blue Earth Diagnostics website. By clicking this link, you will be taken to a website that is independent from Blue Earth Diagnostics. The site you are linking to is not controlled or endorsed by Blue Earth Diagnostics and Blue Earth Diagnostics is not responsible for the content provided on that site.

ACCEPT
CANCEL

PRODUCT PIPELINE


Blue Earth Diagnostics’ commitment is to develop and commercialise innovative radiopharmaceutical agents that have the potential to inform management decisions or treat patients with serious disease, such as cancer. These agents are designed to have a positive impact on patient care, with a focus on areas of significant unmet medical need. Here you can explore details of our research pipeline, arranged by product.

Product/Candidate
DISEASE/THERAPEUTIC AREA
Application
Preclinical
Phase 1
Phase 2
Phase 3

fluciclovine(18F)

Brain metastases

PET imaging

FAP-targeted technology

Multiple solid tumours 
PET imaging

Abbreviations:
PET = Positron Emission Tomography
FAP = Fibroblast Activation Protein

 

Our sister company, Blue Earth Therapeutics, continues to investigate the use of rhPSMA-10.1 as a therapeutic agent. For more information see

https://www.blueearththerapeutics.com/pipeline

 

PP-UK-0618 / May 2023

© 2021 Blue Earth Diagnostics All rights reserved.